Alvimopan, for postoperative ileus following bowel resection

A pooled analysis of phase III studies

Conor P. Delaney, Bruce G. Wolff, Eugene R. Viscusi, Anthony J. Senagore, John G. Fort, Wei Du, Lee Techner, Bruce Wallin

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

OBJECTIVE: To obtain further analysis regarding specific outcomes and alvimopan doses in bowel resection (BR) patients. SUMMARY BACKGROUND DATA: Although postoperative ileus (POI) is common after BR, there is currently no recognized treatment or prevention available. Alvimopan, a novel, peripherally active mu-opioid receptor antagonist, accelerated GI recovery after BR or hysterectomy in 3 phase III trials. METHODS: A pooled retrospective subset analysis of BR patients in alvimopan phase III trials was performed. Randomized BR patients received alvimopan 6 mg (n = 397), 12 mg (n = 413), or placebo (n = 402) ≥2 hours before surgery and twice daily until hospital discharge for ≤7 days. The primary endpoint of each trial was time to recovery of GI function. Hospital discharge order (DCO) written, readmission, and morbidities were also assessed. Cox proportional hazard models were used to analyze treatment effects on time-to-event endpoints. RESULTS: Alvimopan (6 or 12 mg) significantly accelerated GI recovery (GI-3; hazard ratio = 1.28 and 1.38, respectively; P ≤ 0.001 for both). Alvimopan significantly accelerated time to DCO written by 16 hours for 6 mg and 18 hours for 12 mg (P <0.001 for both) from a mean of 147 hours for placebo. Alvimopan-treated patients had reduced postoperative morbidity compared with placebo, and incidence of prolonged hospital stay or readmission was significantly reduced (P <0.001). Tolerability profiles were similar among groups. CONCLUSIONS: Alvimopan significantly accelerated GI recovery in BR patients. A 12-mg dose provided more consistent benefits across both sexes and all ages. Postoperative morbidity rates, prolonged hospital stay, and rates of hospital readmission were significantly reduced. Alvimopan reduces the consequences of POI after BR.

Original languageEnglish (US)
Pages (from-to)355-363
Number of pages9
JournalAnnals of Surgery
Volume245
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

alvimopan
Ileus
Patient Readmission
Placebos
Morbidity
Length of Stay
Narcotic Antagonists
mu Opioid Receptor
Recovery of Function

ASJC Scopus subject areas

  • Surgery

Cite this

Delaney, C. P., Wolff, B. G., Viscusi, E. R., Senagore, A. J., Fort, J. G., Du, W., ... Wallin, B. (2007). Alvimopan, for postoperative ileus following bowel resection: A pooled analysis of phase III studies. Annals of Surgery, 245(3), 355-363. https://doi.org/10.1097/01.sla.0000232538.72458.93

Alvimopan, for postoperative ileus following bowel resection : A pooled analysis of phase III studies. / Delaney, Conor P.; Wolff, Bruce G.; Viscusi, Eugene R.; Senagore, Anthony J.; Fort, John G.; Du, Wei; Techner, Lee; Wallin, Bruce.

In: Annals of Surgery, Vol. 245, No. 3, 03.2007, p. 355-363.

Research output: Contribution to journalArticle

Delaney, CP, Wolff, BG, Viscusi, ER, Senagore, AJ, Fort, JG, Du, W, Techner, L & Wallin, B 2007, 'Alvimopan, for postoperative ileus following bowel resection: A pooled analysis of phase III studies', Annals of Surgery, vol. 245, no. 3, pp. 355-363. https://doi.org/10.1097/01.sla.0000232538.72458.93
Delaney, Conor P. ; Wolff, Bruce G. ; Viscusi, Eugene R. ; Senagore, Anthony J. ; Fort, John G. ; Du, Wei ; Techner, Lee ; Wallin, Bruce. / Alvimopan, for postoperative ileus following bowel resection : A pooled analysis of phase III studies. In: Annals of Surgery. 2007 ; Vol. 245, No. 3. pp. 355-363.
@article{ff0befed69d14797a8856f1a731224b5,
title = "Alvimopan, for postoperative ileus following bowel resection: A pooled analysis of phase III studies",
abstract = "OBJECTIVE: To obtain further analysis regarding specific outcomes and alvimopan doses in bowel resection (BR) patients. SUMMARY BACKGROUND DATA: Although postoperative ileus (POI) is common after BR, there is currently no recognized treatment or prevention available. Alvimopan, a novel, peripherally active mu-opioid receptor antagonist, accelerated GI recovery after BR or hysterectomy in 3 phase III trials. METHODS: A pooled retrospective subset analysis of BR patients in alvimopan phase III trials was performed. Randomized BR patients received alvimopan 6 mg (n = 397), 12 mg (n = 413), or placebo (n = 402) ≥2 hours before surgery and twice daily until hospital discharge for ≤7 days. The primary endpoint of each trial was time to recovery of GI function. Hospital discharge order (DCO) written, readmission, and morbidities were also assessed. Cox proportional hazard models were used to analyze treatment effects on time-to-event endpoints. RESULTS: Alvimopan (6 or 12 mg) significantly accelerated GI recovery (GI-3; hazard ratio = 1.28 and 1.38, respectively; P ≤ 0.001 for both). Alvimopan significantly accelerated time to DCO written by 16 hours for 6 mg and 18 hours for 12 mg (P <0.001 for both) from a mean of 147 hours for placebo. Alvimopan-treated patients had reduced postoperative morbidity compared with placebo, and incidence of prolonged hospital stay or readmission was significantly reduced (P <0.001). Tolerability profiles were similar among groups. CONCLUSIONS: Alvimopan significantly accelerated GI recovery in BR patients. A 12-mg dose provided more consistent benefits across both sexes and all ages. Postoperative morbidity rates, prolonged hospital stay, and rates of hospital readmission were significantly reduced. Alvimopan reduces the consequences of POI after BR.",
author = "Delaney, {Conor P.} and Wolff, {Bruce G.} and Viscusi, {Eugene R.} and Senagore, {Anthony J.} and Fort, {John G.} and Wei Du and Lee Techner and Bruce Wallin",
year = "2007",
month = "3",
doi = "10.1097/01.sla.0000232538.72458.93",
language = "English (US)",
volume = "245",
pages = "355--363",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Alvimopan, for postoperative ileus following bowel resection

T2 - A pooled analysis of phase III studies

AU - Delaney, Conor P.

AU - Wolff, Bruce G.

AU - Viscusi, Eugene R.

AU - Senagore, Anthony J.

AU - Fort, John G.

AU - Du, Wei

AU - Techner, Lee

AU - Wallin, Bruce

PY - 2007/3

Y1 - 2007/3

N2 - OBJECTIVE: To obtain further analysis regarding specific outcomes and alvimopan doses in bowel resection (BR) patients. SUMMARY BACKGROUND DATA: Although postoperative ileus (POI) is common after BR, there is currently no recognized treatment or prevention available. Alvimopan, a novel, peripherally active mu-opioid receptor antagonist, accelerated GI recovery after BR or hysterectomy in 3 phase III trials. METHODS: A pooled retrospective subset analysis of BR patients in alvimopan phase III trials was performed. Randomized BR patients received alvimopan 6 mg (n = 397), 12 mg (n = 413), or placebo (n = 402) ≥2 hours before surgery and twice daily until hospital discharge for ≤7 days. The primary endpoint of each trial was time to recovery of GI function. Hospital discharge order (DCO) written, readmission, and morbidities were also assessed. Cox proportional hazard models were used to analyze treatment effects on time-to-event endpoints. RESULTS: Alvimopan (6 or 12 mg) significantly accelerated GI recovery (GI-3; hazard ratio = 1.28 and 1.38, respectively; P ≤ 0.001 for both). Alvimopan significantly accelerated time to DCO written by 16 hours for 6 mg and 18 hours for 12 mg (P <0.001 for both) from a mean of 147 hours for placebo. Alvimopan-treated patients had reduced postoperative morbidity compared with placebo, and incidence of prolonged hospital stay or readmission was significantly reduced (P <0.001). Tolerability profiles were similar among groups. CONCLUSIONS: Alvimopan significantly accelerated GI recovery in BR patients. A 12-mg dose provided more consistent benefits across both sexes and all ages. Postoperative morbidity rates, prolonged hospital stay, and rates of hospital readmission were significantly reduced. Alvimopan reduces the consequences of POI after BR.

AB - OBJECTIVE: To obtain further analysis regarding specific outcomes and alvimopan doses in bowel resection (BR) patients. SUMMARY BACKGROUND DATA: Although postoperative ileus (POI) is common after BR, there is currently no recognized treatment or prevention available. Alvimopan, a novel, peripherally active mu-opioid receptor antagonist, accelerated GI recovery after BR or hysterectomy in 3 phase III trials. METHODS: A pooled retrospective subset analysis of BR patients in alvimopan phase III trials was performed. Randomized BR patients received alvimopan 6 mg (n = 397), 12 mg (n = 413), or placebo (n = 402) ≥2 hours before surgery and twice daily until hospital discharge for ≤7 days. The primary endpoint of each trial was time to recovery of GI function. Hospital discharge order (DCO) written, readmission, and morbidities were also assessed. Cox proportional hazard models were used to analyze treatment effects on time-to-event endpoints. RESULTS: Alvimopan (6 or 12 mg) significantly accelerated GI recovery (GI-3; hazard ratio = 1.28 and 1.38, respectively; P ≤ 0.001 for both). Alvimopan significantly accelerated time to DCO written by 16 hours for 6 mg and 18 hours for 12 mg (P <0.001 for both) from a mean of 147 hours for placebo. Alvimopan-treated patients had reduced postoperative morbidity compared with placebo, and incidence of prolonged hospital stay or readmission was significantly reduced (P <0.001). Tolerability profiles were similar among groups. CONCLUSIONS: Alvimopan significantly accelerated GI recovery in BR patients. A 12-mg dose provided more consistent benefits across both sexes and all ages. Postoperative morbidity rates, prolonged hospital stay, and rates of hospital readmission were significantly reduced. Alvimopan reduces the consequences of POI after BR.

UR - http://www.scopus.com/inward/record.url?scp=34247589358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247589358&partnerID=8YFLogxK

U2 - 10.1097/01.sla.0000232538.72458.93

DO - 10.1097/01.sla.0000232538.72458.93

M3 - Article

VL - 245

SP - 355

EP - 363

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 3

ER -